July 8, 2019 03:08 PM EDT
Financing

IGM Bio­sciences banks a $103M megaround on its quest to pi­o­neer a new kind of can­cer-fight­ing an­ti­body

Amber Tong

A low-pro­file biotech out to shake up how the in­dus­try imag­ines an­ti­body ther­a­peu­tics is at­tract­ing some eye­balls to­day with a $103 mil­lion megaround.

IGM Bio­sciences …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times